Diabetic retinopathy research could reduce screening costs

May 7, 2012

Research carried out at the Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, has concluded that it would be a safe and cost-effective strategy to screen people with type 2 diabetes who have not yet developed diabetic retinopathy, for the disease once every two years instead of annually.

The research is supported by funding from the National Institute for Health Research Peninsula Collaboration for Leadership in Applied Health Research and Care (NIHR PenCLAHRC). It is published today on-line in .

Diabetic retinopathy is a common complication of . It occurs when high damage the cells in the and, if not treated, can lead to . In all but some cases diabetic retinopathy has a typically slow rate of progression and can take years to develop.

The research team developed a model that simulated the progression of retinopathy in type 2 diabetes and related screening, in order to predict the rates of retinopathy-related sight loss. The model used data from the Royal Devon & Exeter NHS Foundation Trust in the South West of the UK and the research team generated comparative 15-year forecasts to assess the differences between current screening policies and those proposed by the findings of the study.

The study concluded that it is safe to screen patients who have not been diagnosed with retinopathy every two years rather than annually, because the research team found that the proportion of patients who develop retinopathy-related sight loss was no different between the two screening intervals.

Proposed savings for the Royal Devon & Exeter Hospital, for which 3,537 of the patients it screens for retinopathy fell into the remit of this study, would be a reduction in costs from £1.83m a year to £1.36m. The study predicts savings of around 25 per cent based on standard assumptions of screening costs.

According to Diabetes UK, some 2.8m people in the UK have diabetes and 10 per cent of them are diagnosed with retinopathy.

The UK's National Institute for Clinical Excellence introduced guidelines for annual screening, but admits that this frequency is arbitrary and has welcomed research to investigate appropriate intervals between screening appointments.

The study was led by Dr. Daniel Chalk, Associate Research Fellow in Applied Operational Research, Peninsula Collaboration for Health, Operational Research and Development (PenCHORD), PCMD. He said: "This is not the first study to investigate screening for diabetic retinopathy, but it is the first to focus on the group of type 2 diabetics who have not yet been diagnosed for the condition. typically develops at a very slow pace, and as a consequence we wanted to identify whether or not there was any merit in reducing the frequency of screening from annually to every two years."

He added: "We found that there was no perceivable difference in the effectiveness of screening annually or every two years for this particular patient cohort, which would suggest that it would be safe and cost-effective to increase the screening interval to two years. In order to support this, an effective recall system and campaign to impress upon patients the continuing importance of such screening would be beneficial – a lengthening of the screening interval in no way undermines the validity of the screening process itself."

Explore further: With diabetes, untreated depression can lead to serious eye disease

Related Stories

Diabetic polyneuropathy not up with impaired glycemia

March 3, 2012

(HealthDay) -- Although significantly increased in subjects with new diabetes, the rates of typical diabetic polyneuropathy (DPN), retinopathy, and nephropathy are not significantly different between subjects with and without ...

Recommended for you

Which diabetes drug is best?

July 19, 2016

(HealthDay)—No single drug to treat type 2 diabetes stands out from the pack when it comes to reducing the risks of heart disease, stroke or premature death, a new research review finds.

Gut bacteria imbalance increases diabetes risk

July 13, 2016

Currently, scientists think the major contributors to insulin resistance are excess weight and physical inactivity, yet ground-breaking new research by an EU funded European-Chinese team of investigators called MetaHit have ...

Team explores genetic architecture of type 2 diabetes

July 11, 2016

New research from a large international team of scientists offers a more complete picture of the genes responsible for type 2 diabetes, demonstrating that previously identified common alleles shared by many in the world are ...

Normal weight may not protect against diabetes

July 14, 2016

(HealthDay)—Type 2 diabetes has long been considered a disease of the overweight and obese, but a new study challenges that notion. It finds nearly one in five normal-weight people has prediabetes—a condition that can ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.